Use of antidementia agents in vascular dementia: Beyond Alzheimer disease

Mayo Clinic Proceedings

Volumn 81, Issue 10, 2006, Pages 1350-1358

  Farlow, Martin R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NIMODIPINE; NOOTROPIC AGENT; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG EFFECT; DRUG INDICATION; DRUG TOLERABILITY; HUMAN; MULTIINFARCT DEMENTIA; RATING SCALE; REVIEW; STROKE; UNSPECIFIED SIDE EFFECT;

EID: 33749263352     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.10.1350     Document Type: Review

References (80)

1. Fratiglioni L, De Ronchi D, Agüero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging. 1999;15:365-375.
2. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK. Senile dementia of Lewy body type: a clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci. 1990;95:119-139.
3. Román GC. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am. 2002;86:477-499.
4. Rockwood K, Howard K, MacKnight C, Darvesh S. Spectrum of disease in vascular cognitive impairment. Neuroepidemiology. 1999;18:248-254.
5. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA. 1997;277:813-817.
6. Pohjasvaara T, Erkinjuntti T, Vataja R, Kaste M. Dementia three months after stroke: baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort. Stroke. 1997;28:785-792.
7. Breteler MM, Ott A, Hofman A. The new epidemic: frequency of dementia in the Rotterdam Study. Haemostasis. 1998;28:117-123.
8. Williams GR, Jiang JG, Matchar DB, Samsa GP. Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke. 1999;30:2523-2528.
9. Tatemichi TK, Desmond DW, Stern Y, Paik M, Sano M, Bagiella E. Cognitive impairment after stroke: frequency, patterns, and relationship to functional abilities. J Neurol Neurosurg Psychiatry. 1994;57:202-207.
10. Zuccalà G, Onder G, Pedone C, et al, GIFA-ONLUS Study Group. Hypotension and cognitive impairment: selective association in patients with heart failure. Neurology. 2001;57:1986-1992.
11. Román GC. Vascular dementia may be the most common form of dementia in the elderly. J Neurol Sci. 2002;203-204:7-10.
12. Sachdev PS, Brodaty H, Looi JC. Vascular dementia: diagnosis, management and possible prevention. Med J Aust. 1999;170:81-85.
13. Roman GC. Vascular dementia: distinguishing characteristics, treatment, and prevention. J Am Geriatr Soc. 2003;51(5, suppl dementia):S296-S304.
14. Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250-260.
15. Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408-414.
16. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66:137-147.
17. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981;10:122-126.
18. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ. 1978;2:1457-1459.
19. Shinotoh H, Namba H, Fukushi K, et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann Neurol. 2000;48:194-200.
20. Tohgi H, Abe T, Kimura M, Saheki M, Takahashi S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neurol. Transm. 1996;103:1211-1220.
21. Swartz RH, Sahlas DJ, Black SE. Strategic involvement of cholinergic pathways and executive dysfunction: does location of white matter signal hyperintensities matter? J Stroke Cerebrovasc Dis. 2003;12:29-36.
22. Black S, Román GC, Geldmacher DS, et al, Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003 Oct;34:2323-2330. Epub 2003 Sep 11.
23. Wilkinson D, Doody R, Helme R, et al, Donepezil 308 Study Group. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003;61:479-486.
24. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359:1283-1290.
25. Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV, GAL-INT-6 Study Group. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia [published correction appears in Clin Ther. 2003;25:2336]. Clin Ther. 2003;25:1765-1782.
26. Small G, Erkinjuntti T, Kurz A, Lilienfeld S. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease. CNS Drugs. 2003;17:905-914.
27. Kurz AF, Erkinjuntti T, Small GW, Lilienfeld S, Damaraju CR. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. Eur J Neurol. 2003;10:633-640.
28. Moretti R, Torre P, Antonello RM, Cazzato G. Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up [letter]. Eur J Neurol. 2001;8:361-362.
29. Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. An open-label pilot study comparing rivastigmine and low-dose aspirin for the treatment of symptoms specific to patients with subcortical vascular dementia. Curr Therapeut Res. 2002;63:443-458.
30. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci. 2002;203-204:141-146.
31. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen. 2003;18:265-272.
32. Moretti R, Torre P, Antonello RM, et al. Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study. Int J Clin Pract. 2004;58:346-353.
33. Orgogozo J-M, Rigaud A-S, Stöffler A, Möbius H-J, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33:1834-1839.
34. Wilcock G, Möbius HJ, Stöffler A, MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17:297-305.
35. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
36. Schneider LS. An overview of rating scales used in dementia research. Alzheimer Insights [serial online]. October 1996;2(3):1-7.
37. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
38. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
39. Mohs RC, Doody RS, Morris JC, et al, "312" Study Group. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients [published correction appears in Neurology. 2001;57:1942]. Neurology. 2001;57:481-488.
40. Gélinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment for Dementia. Am J Occup Ther. 1999;53:471-481.
41. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J Med Chem. 1995;38:4821-4829.
42. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136-145.
43. Burns A, Rossor M, Hecker J, et al, International Donepezil Study Group. The effects of donepezil in Alzheimer's disease-results from a multinational trial. Dement Geriatr Cogn Disord. 1999;10:237-244.
44. Winblad B, Engedal K, Soininen H, et al, Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57:489-495.
45. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E, Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published correction appears in Neurology. 2001;57:2153]. Neurology. 2001;57:613-620.
46. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004;63:214-219.
47. Farcnik K, Pratt RD, Perdomo CA, Donepezil 307 and 309 VaD Study Groups. Donepezil provides significant benefits on cognition, global function, and activities of daily living in patients with vascular dementia [abstract]. Int Psychogeriatr. 2003;15(suppl 2):256.
48. Raskind MA, Peskind ER, Wessel T, Yuan W, Galantamine USA-1 Study Group. Galantamme in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261-2268.
49. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C, Galantamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54:2269-2276.
50. Wilcock GK, Lilienfeld S, Gaens E, Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial [published correction appears in BMJ. 2001;322:405]. BMJ. 2000;321:1445-1449.
51. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001;71:589-595.
52. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial [published correction appears in BMJ. 2001;322:1456]. BMJ. 1999;318:633-638.
53. Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch Neurol. 2003;60:843-848.
54. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry. 1987;48(suppl):9-15.
55. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982-1983;17:37-49.
56. Ryden MB. Aggressive behavior in persons with dementia who live in the community. Alzheimer Dis Assoc Disord. 1988;2:342-355.
57. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ, Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.
58. Gottfries CG, Brane G, Gullberg B, Steen G. A new rating scale for dementia syndromes. Arch Gerontol Geriatr. 1982;1:311-330.
59. Spiegel R, Brunner C, Ermini-Fünfschilling D, et al. A new behavioral assessment scale for geriatric out- and in-patients: the NOSGER (Nurses' Observation Scale for Geriatric Patients). J Am Geriatr Soc. 1991;39:339-347.
60. Goldsmith DR, Scott LJ. Donepezil: in vascular dementia. Drugs Aging. 2003;20:1127-1136.
61. Johnson KD. Donepezil minimally effective for patients with vascular dementia. J Fam Pract. 2004;53:181-182.
62. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev. 2004;1:CD004395.
63. Mobius HJ, Stoffler A, Graham SM. Memantine hydrochloride: pharmacological and clinical profile. Drugs Today (Barc). 2004;40:685-695.
64. Olsen CE, Poulsen HD, Lublin HK. Drug therapy of dementia in elderly patients: a review. Nord J Psychiatry. 2005;59:71-77.
65. Pratt RD. Patient populations in clinical studies of donepezil in vascular dementia. Int Psychogeriatr. 2003;15(suppl 1):195-200.
66. Pratt RD. Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia. J Neurol Sci. 2002;203-204:57-65.
67. Roman GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord. 2005;20:338-344. Epub 2005 Sep 23.
68. Rossom R, Adityanjee, Dysken M. Efficacy and tolerability of memantine in the treatment of dementia. Am J Geriatr Pharmacother. 2004;2:303-312.
69. Doody RS. Update on Alzheimer drugs (donepezil). Neurologist. 2003;9:225-229.
70. Bullock R, Erkinjuntti T, Lilienfeld S, GAL-INT-6 Study Group. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine. Dement Geriatr Cogn Disord. 2004;17:29-34.
71. Bullock R. Galantamine: use in Alzheimer's disease and related disorders. Expert Rev Neurother. 2004;4:153-163.
72. Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database Syst. Rev. 2006;1:CD004746.
73. Kertesz A. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Curr Neurol Neurosci Rep. 2002;2:503-504.
74. Kurz A. Non-cognitive benefits of galantamine (Reminyl) treatment in vascular dementia. Acta Neurol Scand Suppl. 2002;178:19-24.
75. Marder K. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial [editorial]. Curr Neurol Neurosci Rep. 2002;2:389-390.
76. Craig D, Birks J. Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev. 2005 Apr 18;2:CD004744.
77. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in vascular dementia. Expert Opin Pharmacother. 2004;5:1399-1410.
78. Roman GC. Rivastigmine for subcortical vascular dementia. Expert Rev Neurother. 2005;5:309-313.
79. Vincent S, Lane R. Rivastigmine in vascular dementia. Int Psychogeriatr. 2003;15(suppl 1):201-205.
80. Wezenberg E, Verkes RJ, Sabbe BG, Ruigt GS, Hulstijn W. Modulation of memory and visuospatial processes by biperiden and rivastigmine in elderly healthy subjects. Psychopharmacology (Berl). 2005 Sep;181:582-594. Epub 2005 Oct 12.